Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7315171 | 0.81 | TACR2 (0.45) | TACR2 | |
| SCHEMBL8970883 | 0.77 | F2R (0.36) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL4870085 | 0.76 | TACR2 (0.46) | TACR2 | |
| SCHEMBL756561 | 0.76 | TACR2 (0.46) | TACR2 | |
| SCHEMBL756562 | 0.75 | F2R (0.42) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL8557969 | 0.74 | SLC6A2 (0.37) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL3868548 | 0.74 | ALOX5 (0.47) | — | |
| SCHEMBL4630832 | 0.74 | SLC6A3 (0.35) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL27787946 | 0.73 | CHRNB2 (0.46) | — | |
| SCHEMBL8559300 | 0.73 | F2R (0.52) | ALDH1A1LMNAHTTSMN1; SMN2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954678-B1 | NOVEL NK1 AND NK2 ANTAGONISTS | ABBOTT PRODUCTS GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-1954678-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007063086-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149537-A1 | NK1 and NK2-antagonists and compositions and methods of using the same | HRH2, PROKR2, BDKRB2 | ALDH1A1 1818/4885LMNA 2555/4885HTT 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.